[HTML] thelancet.com

[HTML][HTML] Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Z Temesgen, CD Burger, J Baker, C Polk… - The Lancet …, 2022 - thelancet.com
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …
被引用次数：61 相关文章

[引用][C] Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Z Temesgen, CD Burger, J Baker, C Polk… - The Lancet Respiratory …, 2022 - cir.nii.ac.jp
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3,
randomised, placebo-controlled trial | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
[HTML] thelancet.com

[HTML][HTML] Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Z Temesgen, CD Burger, J Baker, C Polk… - The Lancet …, 2022 - thelancet.com
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.

Z Temesgen, CD Burger, J Baker, C Polk, CR Libertin… - 2022 - cabidigitallibrary.org
Background: The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.

Z Temesgen, CD Burger, J Baker, C Polk… - The Lancet …, 2021 - europepmc.org
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Z Temesgen, CD Burger, J Baker… - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

LIVE-AIR Study Group - The Lancet Respiratory …, 2022 - mayoclinic.elsevierpure.com
Background: The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Z Temesgen, CD Burger, J Baker, C Polk… - The Lancet Respiratory …, 2022 - Elsevier
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …
[HTML] nih.gov

[HTML][HTML] Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Z Temesgen, CD Burger, J Baker, C Polk… - The Lancet …, 2022 - ncbi.nlm.nih.gov
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.

Z Temesgen, C Burger, J Baker, C Polk… - Lancet Respiratory …, 2022 - escholarship.org
BACKGROUND: The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte …